<DOC>
	<DOC>NCT00231348</DOC>
	<brief_summary>The purpose of this study is to determine the effectiveness of nefazadone in patients with social anxiety disorder (SAD).</brief_summary>
	<brief_title>Nefazodone in the Treatment of Social Phobia</brief_title>
	<detailed_description>The purpose of this study is to examine the efficacy of the 5HT2 receptor antagonist nefazadone in SAD, and to explore regional cerebral blood flow in patients with SAD when confronted with a personal phobic stimulus, using positron emission tomography (PET). Changes in cerebral blood flow were correlated with self-rated anxiety measures.</detailed_description>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Nefazodone</mesh_term>
	<criteria>DSMIV diagnosis of generalized social anxiety disorder, males and females between the ages of 1865 A history of bipolar disorder, psychotic illness, or any other anxiety disorders, organic brain disease or active drug or alcohol abuse within one year as assessed by the SCIDP and interview, or a concurrent medical condition that would not be compatible with the study in the opinion of the principal investigator. Patients required to be free of psychotropic or betablocker medication for 2 weeks prior to study. Pts taking fluoxetine required to be drugfree for 6 weeks.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Social anxiety disorder</keyword>
	<keyword>social phobia</keyword>
	<keyword>positron emission tomography (PET</keyword>
	<keyword>regional cerebral blood flow (rCBF)</keyword>
	<keyword>nefazodone</keyword>
	<keyword>amygdala</keyword>
</DOC>